NCT06532149View on ClinicalTrials.gov

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

September 5, 2026

Study Completion Date

September 30, 2026

Conditions
NSCLC Stage IVSex DisorderHypogonadism, MaleErectile Dysfunction
Interventions
DRUG

Alectinib

Alectinib 600 mg/BID

DRUG

Brigatinib

180 mg/daily

DRUG

Lorlatinib 100 mg

100 mg/daily

DRUG

Osimertinib

80 mg/daily

DRUG

Sotorasib

960 mg/daily

DRUG

Dabrafenib

150 mg/BID

DRUG

Trametinib

2 mg/daily

DRUG

Selpercatinib

160 mg/BID

DRUG

Pembrolizumab

200 mg intravenous every 21 days

DRUG

Cemiplimab

350 mg intravenous every 21 days

DRUG

Nivolumab

240 mg intravenous every 14 days

DRUG

Carboplatin

AUC4/AU5 intravenous every 21 days

DRUG

Pemetrexed

500 mg/mq intravenous every 21 days

DRUG

Paclitaxel

175 mg/mq intravenous every 21 days

Trial Locations (1)

00168

RECRUITING

Fondazione Policlinico Gemelli IRCCS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER